Deutsches Krebsforschungszentrum

Dr Jörg Hoheisel’s group at the DKFZ aims to develop and apply new technologies for a description of cellular function and understanding of the regulation of the relevant processes. Systems are developed towards early diagnosis, prognosis and evaluation of the success of treatment, with an emphasis on cancer. In addition to many publications, the work has led to the filing of 42 patent applications. DKFZ is alo partner in the National Center for Tumour Diseases (NCT) in Heidelberg. Dr Hoheisel is member of the NCT Molecular Diagnosis and Responses Prediction Advisory Board. In collaboration with NCT, the binders developed as part of this project will be applied to learn about their usefulness in a clinical environment.
The group has participated in several projects in the area of this proposal. Dr Hoheisel was subcoordinator of the protein array section of the EU MolTools FP6 integrated project and analysed quantitatively the DNA-interaction of transcription factors in Regulatory Genomics (FP6). He is a partner within the EU ProteomeBinders (FP6) coordination activity. He was coordinator of a project within the German Proteome Analysis Programme on isolation and fractionation of complex protein extracts from tissues and selection of binders.
Role in AFFINOMICS: The group will make several contributions to binder characterisation and applications. They will provide peptide antigens in large number within WP1, establish and use arrays of full-length proteins or peptides for binder specificity and QC studies and peptide arrays for epitope mapping in WP3 and WP5. In WP6, they will use the binders produce to analyse functional cell signal transduction protein expression in carcinogenesis.